Ubiquitinaulinastatin suppresses lipopolysaccharide-induced prostaglandin E2 synthesis and nitric oxide production through the downregulation of nuclear factor-kB in BV2 mouse microglial cells

International Journal of Molecular Medicine

Volumn 31, Issue 5, 2013, Pages 1030-1036

  Sung, Yun Hee ^a   Shin, Mal Soon ^b   Ko, Il Gyu ^b   Kim, Sung Eun ^b   Kim, Chang Ju ^b   Ahn, Hyun Jong ^c   Yoon, Hye Sun ^d   Lee, Bong Jae ^e  

^a Kyungnam University   (South Korea)

^b Departments of Physiology   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

^d Eulji General Hospital   (South Korea)

^e Kyung Hee University College of Medicine   (South Korea)

Author keywords

Lipopolysaccharide; Nitric oxide; Nuclear factor kB; Prostaglandin E2; Ulinastatin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; PROSTAGLANDIN E2; ULINASTATIN; DNA; GLYCOPROTEIN; I KAPPA B; INDUCIBLE NITRIC OXIDE SYNTHASE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NOS2 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOSOLIC FRACTION; DOWN REGULATION; GEL MOBILITY SHIFT ASSAY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; CYTOSOL; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MICROGLIA; PROTEIN BINDING;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; CYCLOOXYGENASE 2; CYTOSOL; DINOPROSTONE; DNA; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HUMANS; I-KAPPA B PROTEINS; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN BINDING; RNA, MESSENGER;

EID: 84876120070     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1322     Document Type: Article

References (40)

1. Liu B and Hong JS: Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304: 1-7, 2003.
2. Moon DO, Choi YH, Kim ND, Park YM and Kim GY: Anti-inflammatory effects of β-lapachone in lipopolysaccharide-stimulated BV2 microglia. Int Immunopharmacol 7: 506-514, 2007.
3. Kubes P and McCafferty DM: Nitric oxide and intestinal inflammation. Am J Med 109: 150-158, 2000.
4. Lee AK, Sung SH, Kim YC and Kim SG: Inhibition of lipopolysaccharide- inducible nitric oxide synthase, TNF-α and COX-2 expression by sauchinone effects on I-κBα phosphorylation, C/EBP and AP-1 activation. Br J Pharmacol 139: 11-20, 2003.
5. Palladino MA, Bahjat FR, Theodorakis EA and Moldawer LL: Anti-TNF-α therapies: the next generation. Nat Rev Drug Discov 2: 736-746, 2003.
6. Kalmar B, Kittel A, Lemmens R, Kornyei Z and Madarasz E: Cultured astrocytes react to LPS with increased cyclooxygenase activity and phagocytosis. Neurochem Int 38: 453-461, 2001.
7. Park HJ, Kim IT, Won JH, Jeong SH, Park EY, Nam JH, Choi J and Lee KT: Anti-inflammatory activities of ent-16αH,17-hydroxy-kauran-19-oic acid isolated from the roots of Siegesbeckia pubescens are due to the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-κB inactivation. Eur J Pharmacol 558: 185-193, 2007.
8. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK and Lee SS: Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation. Mutat Res 480-481: 243-268, 2001.
9. Bredt DS and Snyder SH: Nitric Oxide: a physiologic messenger molecule. Annu Rev Biochem 63: 175-195, 1994.
10. Xie Q and Nathan C: The high-output nitric oxide pathway: role and regulation. J Leukoc Biol 56: 576-582, 1994.
11. Lappas M, Permezel M, Georgiou HM and Rice GE: Nuclear factor kappa B regulation of proinflammatory cytokines in human gestational tissues in vitro. Biol Reprod 67: 668-673, 2002.
12. Karin M: The beginning of the end: IκB kinase (IKK) and NF-κB activation. J Biol Chem 274: 27339-27342, 1999.
13. Maciejewski R, Burdan F, Burski K, Madej B, Ziemiakowicz R, Dabrowski A and Wallner G: Selected biochemical parameters and ultrastructural picture of pancreas due to Ulinastatin treatment of experimental acute pancreatitis. Exp Toxicol Pathol 56: 305-311, 2005.
14. Tani T, Aoki H, Yoshioka T, Lin KJ and Kodama M: Treatment of septic shock with a protease inhibitor in a canine model: a prospective, randomized, controlled trial. Crit Care Med 21: 925-930, 1993.
15. Masuda T, Sato K, Noda C, Ikeda KM, Matsunaga A, Ogura MN, Shimizu K, Nagasawa H, Matsuyama N and Izumi T: Protective effect of urinary trypsin inhibitor on myocardial mitochondria during hemorrhagic shock and reperfusion. Crit Care Med 31: 1987-1992, 2003.
16. Yano T, Anraku S, Nakayama R and Ushijima K: Neuroprotective effect of urinary trypsin inhibitor against focal cerebral ischemia-reperfusion injury in rats. Anesthesiology 98: 465-473, 2003.
17. Shin IW, Jang IS, Lee SM, Park KE, Ok SH, Sohn JT, Lee HK and Chung YK: Myocardial protective effect by ulinastatin via an anti-inflammatory response after regional ischemia/reperfusion injury in an in vivo rat heart model. Korean J Anesthesiol 61: 499-505, 2011.
18. Molor-Erdene P, Okajima K, Isobe H, Uchiba M, Harada N and Okabe H: Urinary trypsin inhibitor reduces LPS-induced hypotension by suppressing tumor necrosis factor-α production through inhibition of Egr-1 expression. Am J Physiol Heart Circ Physiol 288: H1265-H1271, 2005.
19. Tanaka Y, Maehara S, Sumi H, Toki N, Moriyama S and Sasaki K: Purification and partial characterization of two forms of urinary trypsin inhibitor. Biochim Biophys Acta 705: 192-199, 1982.
20. Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N, Nishiyama M, Hatai Y, Asano Y, Kobayashi T, Takeshita S and Nonoyama S: Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation 124: 2822-2828, 2011.
21. Gao C, Li R and Wang S: Ulinastatin protects pulmonary tissues from lipopolysaccharide-induced injury as an immunomodulator. J Trauma Acute Care Surg 72: 169-176, 2012.
22. Inoue K, Takano H, Shimada A, Yanagisawa R, Sakurai M, Yoshino S, Sato H and Yoshikawa T: Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Mol Pharmacol 67: 673-680, 2005.
23. Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichimaru T, Fujita I, Tasaki H and Miyazaki S: Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis 181: 1101-1109, 2000.
24. Nakamura H, Abe S, Shibata Y, Sata M, Kato S, Saito H, Hino T, Takahashi H and Tomoike H: Inhibition of neutrophil elastase-induced interleukin-8 gene expression by urinary trypsin inhibitor in human bronchial epithelial cells. Int Arch Allergy Immunol 112: 157-162, 1997.
25. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C and Matsumoto A: Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 15: 101-105, 2001.
26. Qiu X, Ji S, Wang J, Li H, Xia T, Pan B, Xiao S and Xia Z: The therapeutic efficacy of Ulinastatin for rats with smoking inhalation injury. Int Immunopharmacol 14: 289-295, 2012.
27. Xu CE, Zhang MY, Zou CW and Guo L: Evaluation of the pharmacological function of ulinastatin in experimental animals. Evaluation of the pharmacological function of ulinastatin in experimental animals. Molecules 17: 9070-9080, 2012.
28. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS and van de Putte LB: Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 43: 4-13, 2000.
29. Hinz B, Brune K and Pahl A: Prostaglandin E2 upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated raw 264.7 macrophages. Biochem Biophys Res Commun 272: 744-748, 2000.
30. Ohshima H and Bartsch H: Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 305: 253-264, 1994.
31. Salerno L, Sorrenti V, Di Giacomo C, Romeo G and Siracusa MA: Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Des 8: 177-200, 2002.
32. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG and Needleman P: Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 90: 7240-7244, 1993.
33. Jun CD, Choi BM, Kim HM and Chung HT: Involvement of protein kinase C during taxol-induced activation of murine peritoneal macrophages. J Immunol 154: 6541-6547, 1995.
34. White KE, Ding Q, Moore BB, Peters-Golden M, Ware LB, Matthay MA and Olman MA: Prostaglandin E2 mediates IL-1β-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors. J Immunol 180: 637-646, 2008.
35. Petrova TV, Akama KT and Van Eldik LJ: Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric oxide synthase by 15-deoxy-Δ12,14-prostaglandin J2. Proc Natl Acad Sci USA 96: 4668-4673, 1999.
36. Ye SM and Johnson RW: Regulation of interleukin-6 gene expression in brain of aged mice by nuclear factor κB. J Neuroimmunol 117: 87-96, 2001.
37. Baeuerle PA and Baltimore D: NF-κB: ten years after. Cell 87: 13-20, 1996.
38. Dijkstra G, Moshage H and Jansen PL: Blockade of NF-κB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? Scand J Gastroenterol Suppl 236: 37-41, 2002.
39. Simmonds RE and Foxwell BM: Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation. Rheumatology 47: 584-590, 2008.
40. Wang H, Sun X, Gao F, Zhong B, Zhang YH and Sun Z: Effect of ulinastatin on growth inhibition, apoptosis of breast carcinoma cells is related to a decrease in signal conduction of JNk-2 and NF-κB. J Exp Clin Cancer Res 31: 2, 2012.